Breast Cancer Research and Treatment

, Volume 131, Issue 2, pp 483–490 | Cite as

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer

  • Yunwei Han
  • Zhihao Yu
  • Shaoyan Wen
  • Bin Zhang
  • Xuchen Cao
  • Xin Wang
Clinical Trial


Neutropenia is one of the most important dose-limiting toxicities and often the reason for dose reduction. In this study we aimed to assess whether chemotherapy-induced neutropenia could be a marker of efficacy and associate with increased survival. Data from a retrospective survey for early breast cancer patients in our hospital were reviewed. Three hundred and thirty-five patients who had been treated with six cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF) were studied. The association between chemotherapy-induced neutropenia and overall survival (OS) was assessed. According to a multivariate Cox model with time-varying covariates, hazard ratios of death were 0.434 (95% confidence interval (CI), 0.298–0.634; P < 0.001) for patients with mild neutropenia, and 0.640 (95% CI, 0.42–0.975; P = 0.038) for those with severe neutropenia. Neutropenia occurring in early breast cancer patients is an independent predictor of increased survival. These findings suggest that neutropenia in patients who receive chemotherapy is strongly associated with a better prognosis.


Breast cancer Adjuvant chemotherapy Neutropenia Prognosis Time-dependent variable 



This study is supported by The Science Technology Development Project of Colleges and Universities in Tianjin [20090139] and Talented Professionals Scientific Research Funds of Tianjin Medical University Cancer Institute and Hospital. The authors would like to thank Yue Li, Hongmeng Zhao, Yanqun Song for their help with data collecting.

Conflict of interest

None of the authors has any competing interest to declare. The authors have no relevant financial interests to disclose.


  1. 1.
    Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942CrossRefGoogle Scholar
  3. 3.
    (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717Google Scholar
  4. 4.
    Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14:833–842PubMedCrossRefGoogle Scholar
  5. 5.
    Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669–677PubMedCrossRefGoogle Scholar
  6. 6.
    Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2007) Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 97:37–42PubMedCrossRefGoogle Scholar
  7. 7.
    Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, Sato Y, Najima M, Ura T, Muro K (2009) Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 45:1757–1763PubMedCrossRefGoogle Scholar
  8. 8.
    Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301–305PubMedCrossRefGoogle Scholar
  9. 9.
    Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80:1763–1766PubMedCrossRefGoogle Scholar
  10. 10.
    Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89:1837–1842PubMedCrossRefGoogle Scholar
  11. 11.
    Ishitobi M, Komoike Y, Motomura K, Koyama H, and Inaji H Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 78:213–219Google Scholar
  12. 12.
    Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914–1921PubMedCrossRefGoogle Scholar
  13. 13.
    Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRefGoogle Scholar
  14. 14.
    Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, Verma S (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886–898PubMedCrossRefGoogle Scholar
  15. 15.
    Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD, Jackisch C (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299–1309PubMedCrossRefGoogle Scholar
  16. 16.
    Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228–237PubMedCrossRefGoogle Scholar
  17. 17.
    Kvinnsland S (1999) The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80:1681PubMedCrossRefGoogle Scholar
  18. 18.
    Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91:2246–2257PubMedCrossRefGoogle Scholar
  19. 19.
    Nakata B, Tsuji A, Mitachi Y, Yamamitsu S, Hirata K, Takeuchi T, Shirasaka T, Hirakawa K (2006) Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer. Clin Oncol (R Coll Radiol) 18:678–683CrossRefGoogle Scholar
  20. 20.
    Fumoleau P, Devaux Y, Vo Van ML, Kerbrat P, Fargeot P, Schraub S, Mihura J, Namer M, Mercier M (1993) Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group. Drugs 45(Suppl 2):38–45PubMedCrossRefGoogle Scholar
  21. 21.
    Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253–1259PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858–1869PubMedGoogle Scholar
  23. 23.
    Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384–1391PubMedCrossRefGoogle Scholar
  24. 24.
    Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590–2611PubMedGoogle Scholar
  25. 25.
    Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86:1297–1302PubMedCrossRefGoogle Scholar
  26. 26.
    Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16:2297–2298PubMedGoogle Scholar
  27. 27.
    Newell DR (2002) Getting the right dose in cancer chemotherapy–time to stop using surface area? Br J Cancer 86:1207–1208PubMedCrossRefGoogle Scholar
  28. 28.
    de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733–3739PubMedGoogle Scholar
  29. 29.
    Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, Shepherd FA (2005) Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23:850–856PubMedCrossRefGoogle Scholar
  30. 30.
    Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg S B, Bengtsson N O, Jakobsen E, Moller S, Lindman H, and Blomqvist C Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncol 50:329–337Google Scholar
  31. 31.
    Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRefGoogle Scholar
  32. 32.
    Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 94:1883–1888PubMedCrossRefGoogle Scholar
  33. 33.
    Gurney H (2006) Developing a new framework for dose calculation. J Clin Oncol 24:1489–1490PubMedCrossRefGoogle Scholar
  34. 34.
    Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299–2304PubMedGoogle Scholar
  35. 35.
    Sandstrom M, Freijs A, Larsson R, Nygren P, Fjallskog ML, Bergh J, Karlsson MO (1996) Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14:1581–1588PubMedGoogle Scholar
  36. 36.
    Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58:143–156PubMedCrossRefGoogle Scholar
  37. 37.
    Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531PubMedCrossRefGoogle Scholar
  38. 38.
    Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311PubMedCrossRefGoogle Scholar
  39. 39.
    Leonard RC, Miles D, Thomas R, Nussey F (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89:2062–2068PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Yunwei Han
    • 1
  • Zhihao Yu
    • 1
  • Shaoyan Wen
    • 1
  • Bin Zhang
    • 1
  • Xuchen Cao
    • 1
  • Xin Wang
    • 1
  1. 1.First Department of Breast Tumor, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Breast Cancer Prevention and TherapyTianjin Medical University, Ministry of EducationTianjinChina

Personalised recommendations